Compare Ascendis Pharma A/S (ASND) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Monolithic Power Systems Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Monolithic Power Systems Inc trades at $1,307.71 (market cap $66.46B). The key difference: Monolithic Power Systems Inc is far larger — about 3.7× Ascendis Pharma A/S's market cap, and Monolithic Power Systems Inc pays a 0.59% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MPWR | |
|---|---|---|
Market Cap | $17.74B | $66.46B |
Sector | Health | Utilities |
52-Week High | $277.18 | $1.69K |
52-Week Low | $163.32 | $711.24 |
Enterprise Value | $18.11B | $65.11B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MPWR trades at $1,352.74, down 1.56% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company demonstrates strong profitability with a 22.98% net income margin and consistent earnings beats in recent quarters. Analyst sentiment is overwhelmingly positive with 88% buy ratings and a consensus price target of $1,760. Recent news highlights ongoing investigations into corporate governance alongside positive coverage of AI infrastructure growth opportunities.
The outlook for MPWR remains favorable given its earnings momentum and positioning in AI and power management semiconductors. Key opportunities include expanding demand in data centers and telecom, while risks involve high valuation multiples and corporate governance scrutiny. The stock offers growth potential but requires monitoring of execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
